Pro Medicus is a health information services business based in Australia. Pro Medicus shares (PME) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Pro Medicus has a trailing 12-month revenue of around $142.1 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Pro Medicus, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $58.3607 - $111.7 |
|---|---|
| 50-day moving average | $101.3742 |
| 200-day moving average | $87.1876 |
| Target price | $96.76 |
| PE ratio | 149.5224 |
| Dividend yield | $0.35 (0.36%) |
| Earnings per share (TTM) | $0.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$104.1
| 1 week (2024-04-16) | 2.06% |
|---|---|
| 1 month (2024-03-22) | 8.21% |
| 3 months (2024-01-24) | 3.37% |
| 6 months (2023-10-24) | 33.80% |
| 1 year (2023-04-24) | 64.79% |
|---|---|
| 2 years (2022-04-22) | 109.29% |
| 3 years (2021-04-23) | 118.51% |
| 5 years (2019-04-24) | 456.39% |
Valuing Pro Medicus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pro Medicus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pro Medicus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 150x. In other words, Pro Medicus shares trade at around 150x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pro Medicus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $96.1 million (£0.0 million).
The EBITDA is a measure of a Pro Medicus's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $142.1 million |
|---|---|
| Operating margin TTM | 66.03% |
| Gross profit TTM | $126.8 million |
| Return on assets TTM | 30.78% |
| Return on equity TTM | 50.49% |
| Profit margin | 49.05% |
| Book value | 1.525 |
| Market capitalisation | $10.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 51.8% of net profits
Recently Pro Medicus has paid out, on average, around 51.8% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pro Medicus shareholders could enjoy a 0.36% return on their shares, in the form of dividend payments. In Pro Medicus's case, that would currently equate to about A$0.35 per share.
Pro Medicus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 28 February 2024 (the "ex-dividend date").
Over the last 12 months, Pro Medicus's shares have ranged in value from as little as $58.3607 up to $111.7. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Pro Medicus's is 0.474. This would suggest that Pro Medicus's shares are less volatile than average (for this exchange).
Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
AMP Ltd Preferred
AUD104.90
ANZ Group Holdings Ltd. Pfd.
AUD103.35
Challenger Ltd Preferred
AUD105.11
Macquarie Bank Ltd Pref
AUD106.27
Macquarie Group Ltd Pref C
AUD102.98
Macquarie Group Ltd Pref
AUD105.90
Macquarie Group Preferred
AUD102.66
Macquarie Group Limited
AUD105.62
Suncorp Group Ltd Pref
AUD100.61
Westpac Banking Corp Pref
AUD102.93
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.